Endocrinology

Karen O. Klein, MD, and Kent L. Reifschneider, MD, discuss a central precocious puberty (CPP) patient case regarding factors that would lead a physician to either stop treating a patient or continue with treatment.

Karen O. Klein, MD, and Kent L. Reifschneider, MD, discuss a central precocious puberty (CPP) patient case regarding factors that would lead a physician to treat a patient.

Karen O. Klein, MD, and Kent L. Reifschneider, MD, discuss individualizing treatment decisions in girls with central precocious puberty (CPP).

Rural patients identifying as Black had a more than 10% absolute increased risk of major leg amputation or death compared with the overall cohort with diabetic foot ulcers.

Our endocrine month in review spotlights the most popular articles from the past month. This month's top articles include a multipart video series, new diabetes, information on osteoporosis, and more!

The estimated annual progression rate to diabetes in older adults with HbA1c-defined prediabetes was 5.3%.

An analysis of data from a 5000-patient cohort suggests use of NSAIDs was associated with a detrimental effect on the benefit of clodronate on reducing risk of fracture among older women.

A 12-month quality improvement project provides insight into the effects of using CGM and supplemental dietary counseling on glycemic control in adult T2D patients with suboptimal glycemic control.

From 2014 to 2020, there was significant increase in the frequency of preeclampsia or gestational hypertension, transfusion, preterm birth <37 weeks, and NICU admission.

An observational study from Portugal indicates GnRHa therapy as a treatment for central precocious puberty was associated with an increase in body weight that subsided 1 year after treatment cessation.

Data from a cross-sectional study from a children's hospital in Shanghai details the increased rate of diagnosis and differences in clinical features of girls diagnosed with precocious puberty during the pandemic against prepandemic periods.

Data from an analysis of a SWAN substudy suggests increased exposure to PFAS was linked to an increased risk of incident diabetes during midlife among women.

The protocol appeared safe, with no associated increases in the incidence of hypoglycemic events during hospitalization or 30-day mortality.

The prevalence of NAFLD in the pediatric population has increased in recent years.

The latest endocrine case report features a patient in their mid-40’s with a history of diabetes and recent elbow I&D for an abscess is called back to the ER for wound culture. Can you determine the best treatment strategy?

There are now more insulin options for patients with diabetes than ever before.

Dr. Jabbour discusses unmet needs in diabetes care and starting insulin therapy.

An analysis of more than 100 mother-child pairs from Colorado found children with fetal exposure to cannabis had increased fat mass and fasting glucose levels compared to their counterparts without fetal exposure to cannabis.

On March 29, Antares Pharma announced the FDA granted approval to their oral testosterone replacement therapy option, testosterone udecanoate (TLANDO), for conditions associated with a deficiency or absence of endogenous testosterone or hypogonadism in adult males.

The therapy is indicated for conditions associated with hypogonadism in adult males.

With the newest indication, the GLP-1 agonist is now available in 3 different doses for diabetic adults.

Data from a new study indicates human behavior and decision-making could be hampering the ability of new diabetes technologies to reduce hypoglycemic events in patients with type 1 diabetes.

Severe and level 2 hypoglycemia has continued to occur in individuals with type 1 diabetes and high hypoglycemia risks despite technological advancements.

Children exposed and not exposed to neonatal hypoglycemia did not have significant differences in rates of low educational performance at 9 to 10 years old.

Higher BMI in overweight category at midlife was associated with a greater burden of overall and CVD morbidity, as well as higher health care costs in older adulthood.

A user fee goal date of August 17, 2022 has been assigned to teplizumab.

After a review of the available evidence, the USPSTF concluded there was insufficient evidence to provide recommendations on screening for eating disorders among adults and adolescents.

Data from the PROMISE study provide clinicians with comprehensive insight into the safety and accuracy of the 180-day CGM system from Eversense in patients with diabetes.

After previous studies found an increase in the diagnosis of central precocious puberty, investigators launched a new study to assess whether decreases in physical activity might be linked to the increased diagnosis rate.

A case-control study provides insight into the diagnostic utility of triptorelin-stimulated luteinizing hormone concentrations for diagnosis of central precocious puberty in girls.